160 related articles for article (PubMed ID: 7820136)
1. Stage I nonseminomatous germ-cell testicular cancer--management options and risk-benefit considerations.
Donohue JP; Thornhill JA; Foster RS; Rowland RG; Bihrle R
World J Urol; 1994; 12(4):170-6; discussion 177. PubMed ID: 7820136
[TBL] [Abstract][Full Text] [Related]
2. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989.
Donohue JP; Thornhill JA; Foster RS; Rowland RG; Bihrle R
Br J Urol; 1993 Mar; 71(3):326-35. PubMed ID: 8386580
[TBL] [Abstract][Full Text] [Related]
3. Stage II nonseminomatous germ-cell testicular tumors--the Indiana experience and risk-benefit analysis.
Foster RS; Bihrle R; Little JS; Rowland RG; Donohue JP
World J Urol; 1994; 12(3):143-6; discussion 147. PubMed ID: 7524921
[TBL] [Abstract][Full Text] [Related]
4. Clinical stage I nonseminomatous germ cell tumors of the testis in childhood and adolescence: an analysis of 31 cases.
Terenziani M; Piva L; Spreafico F; Salvioni R; Massimino M; Luksch R; Cefalo G; Casanova M; Ferrari A; Polastri D; Mazza E; Bellani FF; Nicolai N
J Pediatr Hematol Oncol; 2002; 24(6):454-8. PubMed ID: 12218592
[TBL] [Abstract][Full Text] [Related]
5. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989).
Donohue JP; Thornhill JA; Foster RS; Bihrle R; Rowland RG; Einhorn LH
J Urol; 1995 Jan; 153(1):85-9. PubMed ID: 7966799
[TBL] [Abstract][Full Text] [Related]
6. Cost and risk benefit in the management of clinical stage II nonseminomatous testicular tumors.
Baniel J; Roth BJ; Foster RS; Donohue JP
Cancer; 1995 Jun; 75(12):2897-903. PubMed ID: 7773940
[TBL] [Abstract][Full Text] [Related]
7. Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer.
Thijssens K; Vaneerdeweg W; Schrijvers D; Eyskens E; Van Oosterom A
Acta Chir Belg; 2003; 103(6):599-602. PubMed ID: 14743567
[TBL] [Abstract][Full Text] [Related]
8. Laparoscopic retroperitoneal lymph node dissection combined with adjuvant chemotherapy for pathological stage II disease in nonseminomatous germ cell tumours: a 15-year experience.
Cresswell J; Scheitlin W; Gozen A; Lenz E; Teber D; Rassweiler J
BJU Int; 2008 Sep; 102(7):844-8. PubMed ID: 18537954
[TBL] [Abstract][Full Text] [Related]
9. Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors.
Spermon JR; Roeleveld TA; van der Poel HG; Hulsbergen-van de Kaa CA; Ten Bokkel Huinink WW; van de Vijver M; Witjes JA; Horenblas S
Urology; 2002 Jun; 59(6):923-9. PubMed ID: 12031382
[TBL] [Abstract][Full Text] [Related]
10. Evolution and controversies in the management of low-stage nonseminomatous germ-cell tumors of the testis.
Pizzocaro G; Nicolai N; Salvioni R
World J Urol; 1994; 12(3):113-9. PubMed ID: 7524920
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
12. The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumors (NSGCTT).
Ondrus D; Goncalves F; Kausitz J; Mat'oska J; Belan V
Neoplasma; 1996; 43(3):195-7. PubMed ID: 8841507
[TBL] [Abstract][Full Text] [Related]
13. A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only.
Nicolai N; Miceli R; Artusi R; Piva L; Pizzocaro G; Salvioni R
J Urol; 2004 Jan; 171(1):172-6. PubMed ID: 14665870
[TBL] [Abstract][Full Text] [Related]
14. Clinical stage I nonseminomatous testicular germ-cell tumors: surgery or watchful waiting, still an issue?
Heidenreich A
Curr Opin Urol; 2002 Sep; 12(5):427-30. PubMed ID: 12172431
[TBL] [Abstract][Full Text] [Related]
15. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group.
Heidenreich A; Albers P; Hartmann M; Kliesch S; Kohrmann KU; Krege S; Lossin P; Weissbach L;
J Urol; 2003 May; 169(5):1710-4. PubMed ID: 12686815
[TBL] [Abstract][Full Text] [Related]
16. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
17. Modeling the cost of management options for stage I nonseminomatous germ cell tumors: a decision tree analysis.
Link RE; Allaf ME; Pili R; Kavoussi LR
J Clin Oncol; 2005 Aug; 23(24):5762-73. PubMed ID: 16110033
[TBL] [Abstract][Full Text] [Related]
18. Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection.
Donohue JP; Thornhill JA; Foster RS; Rowland RG; Bihrle R
Eur J Cancer; 1995 Sep; 31A(10):1599-604. PubMed ID: 7488408
[TBL] [Abstract][Full Text] [Related]
19. Laparoscopic retroperitoneal lymphadenectomy for stage I non-seminomatous testicular tumors.
Custureri F; Urciuoli P; Iavarone C; D'Orazi V; Gabatel R; Ghinassi S; Patrizi G; Palazzini G; Di Matteo FM; Peparini N
Hepatogastroenterology; 2005; 52(66):1677-80. PubMed ID: 16334755
[TBL] [Abstract][Full Text] [Related]
20. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
